Rhythm’s lead asset, IMCIVREE ® (setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the U.S. Food and Drug Administration (FDA) to reduce excess body ...
"Based on the unmet need and severity of Prader-Willi syndrome and learnings from our initial study, we plan to initiate an ...
Rhythm Pharmaceuticals (RYTM) announced that it reacquired the rights to Imcivree in China, including mainland China, Hong Kong and Macau, as ...
Preliminary net revenues from worldwide sales of Imcivree (setmelanotide) were around $42 million for the fourth quarter of 2024 and approximately $130 million for the full year of 2024.
today announced that it reacquired the rights to IMCIVREE ® (setmelanotide) in China, including mainland China, Hong Kong and Macau, as the Company agreed to terminate its 2021 licensing ...
today announced that it reacquired the rights to IMCIVREE® (setmelanotide) in China, including mainland China, Hong Kong and Macau, as the Company agreed to terminate its 2021 licensing agreement ...
Rhythm’s lead asset, IMCIVREE ® (setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the U.S. Food and Drug Administration (FDA) to reduce excess ...
today announced that it reacquired the rights to IMCIVREE ® (setmelanotide) in China, including mainland China, Hong Kong and Macau, as the Company agreed to terminate its 2021 licensing agreement ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback